$599

Novo Initiates Ph3 OASIS 5 Study; AZ Initiates Ph3 Amylin Program; Roche Makes Another Manufacturing Investment; NICE Endorses Lilly’s QW Insulin; Hansoh Discovers New Obesity Assets

A series of cardiometabolic-related news items has been observed from Novo Nordisk, AstraZeneca, Roche/Genentech, Lilly, and Hansoh Pharmaceuticals. Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.
Already a member? Log in here